Clinical Trials /

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

NCT03913026

Description:

Allogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is associated with a lower risk of relapse, especially in the presence of minimal residual disease in the setting of acute leukemia and myelodysplasia. Furthermore, CB has the added advantage of being associated with a low risk of chronic graft versus host disease (GVHD). Unfortunately, CB transplants are hampered by a higher risk of transplant related mortality (TRM) when compared to bone marrow/peripheral blood transplants because of the limited cell dose of CB. In the previous UM171 trial (NCT02668315), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22 patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and 74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were 5 patients who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute leukemia/aggressive lymphoma. Despite this high risk population, progression was 20% at 12 months. Hence, in this new trial, investigators are targeting patients with high and very high-risk acute leukemia/myelodysplasia to test the antileukemia effect of this new graft, a UM171 expanded CB.

Related Conditions:
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Secondary Acute Myeloid Leukemia
  • Therapy-Related Acute Myeloid Leukemia
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia
  • Official Title: A Phase II Open-label Study of ECT-001-expanded Cord Blood Transplantation in Patients With High-risk Acute Leukemia/Myelodysplasia

Clinical Trial IDs

  • ORG STUDY ID: ECT-001-CB.002
  • NCT ID: NCT03913026

Conditions

  • High Risk Hematologic Malignancy
  • Cord Blood Transplant

Interventions

DrugSynonymsArms
Transplant with an expanded ECT-001 cord bloodMain intervention

Purpose

Allogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is associated with a lower risk of relapse, especially in the presence of minimal residual disease in the setting of acute leukemia and myelodysplasia. Furthermore, CB has the added advantage of being associated with a low risk of chronic graft versus host disease (GVHD). Unfortunately, CB transplants are hampered by a higher risk of transplant related mortality (TRM) when compared to bone marrow/peripheral blood transplants because of the limited cell dose of CB. In the previous UM171 trial (NCT02668315), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22 patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and 74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were 5 patients who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute leukemia/aggressive lymphoma. Despite this high risk population, progression was 20% at 12 months. Hence, in this new trial, investigators are targeting patients with high and very high-risk acute leukemia/myelodysplasia to test the antileukemia effect of this new graft, a UM171 expanded CB.

Detailed Description

      Methodology:

      This is a multi-center open label phase II clinical trial. Patients with high and very
      high-risk acute leukemia/myelodysplasia will receive a single 5-7/8 HLA matched ECT-001
      (UM171) expanded cord blood after an ablative conditioning regimen. This group of patients
      would be expected to have poor progression free survival (PFS) after a conventional
      allogeneic transplant (bone marrow-peripheral blood).

      Investigators key primary and secondary objectives include:

        1. To confirm low Transplant Related Mortality (TRM)

        2. To evaluate relapse free survival (RFS)

        3. To analyze kinetics of hematologic engraftment;

        4. To evaluate the incidence of acute and chronic GVHD

        5. To evaluate the safety of the procedure

        6. To evaluate incidence of infectious complications

        7. To analyze duration of hospitalization

        8. To evaluate the incidence of pre-engraftment/engraftment syndrome (PES/ES)

        9. To analyze the effect of cryopreservation of the expanded CD34+ fraction on safety and
           efficacy endpoints
    

Trial Arms

NameTypeDescriptionInterventions
Main interventionExperimentalEligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
  • Transplant with an expanded ECT-001 cord blood

Eligibility Criteria

        Inclusion Criteria:

          1. Presence of high-risk acute leukemia/myelodysplasia defined as one of the following:

             I. Acute Myeloid Leukemia:

               1. Primary induction failure (no CR or CRi after ≥ 2 courses of induction therapy or
                  after ≥ 1 induction containing high dose Ara-C)

               2. Chemorefractory relapse (no CR or CRi after 1 chemointensive treatment)

               3. Relapse after allogeneic or autologous transplant

               4. High risk AML in CR1: i) any adverse genetic abnormality as defined by European
                  Leukemia Net excluding FLT3 mutation; ii) secondary or therapy related AML
                  excluding good risk genetic abnormalities (as defined by ELN); or iii) any other
                  poor risk feature known to be associated with a PFS or DFS ≤40% at 2 years after
                  conventional transplantation.

               5. CR2 excluding good risk genetic abnormalities defined by ELN

               6. ≥CR3

             II. Acute Lymphoid Leukemia

               1. Primary induction failure (≥ 2 inductions)

               2. Chemorefractory relapse (at least 1 intensive induction chemotherapy;
                  blinatumomab, inotuzumab or CAR-T cells may be considered as an equivalent)

               3. Relapse after allogeneic or autologous transplant

               4. High risk ALL in CR1: Ph like ALL or any other poor risk feature known to be
                  associated with an PFS or DFS ≤40% at 2 years after conventional transplantation.

               5. ≥CR2

               6. MRD+ within 1 month of start of conditioning regimen.

             III. Myelodysplastic syndrome

               1. Relapse after allogeneic or autologous transplant

               2. ≥10 % blasts within 1 month of start of conditioning regimen

               3. Very poor cytogenetics (>3 abnormalities)

               4. Any poor risk feature known to be associated with a PFS or DFS ≤40% at 2 years
                  after conventional transplantation

               5. TP53 mutation

               6. ≥40 years old and RAS or JAK2 mutation

               7. CMML with HCT-specific CPSS score high or intermediate-2

               8. Stable disease (absence of CR/PR/HI) after 6 cycles of azacitidine (or another
                  demethylating agent)

               9. Progressive disease while on azacitidine (or another demethylating agent)

          2. 18-70 years old

          3. Availability of 2 CBs ≥ 4/8 HLA match when A, B, C and DRB1 are performed at the
             allele level.

             I. Cord to be expanded:

               1. CD34+ cell count >0.5 x 105/kg and TNC>1.5 x 107/kg (these numbers are all
                  pre-freeze)

               2. Needs to be erythrodepleted by bank prior to cryopreservation

               3. Must come from a cord bank that is FACT (Foundation for the Accreditation of
                  Cellular Therapy) accredited, FDA approved or eligible for NMDP IND.

             II. Non-expanded CB/back-up cord:

               1. Pre-freeze TNC count ≥ 2.0 x 107/kg with CD34+ cells ≥1.5 x 105/kg or TNC count ≥
                  1.5 x 107 TNC/kg with CD34+ cells ≥1.7 x 105/kg. If a single cord does not meet
                  these criteria, 2 back up cords will be an acceptable alternative with a minimum
                  for each of 1.5 x 107/kg TNC and 1 x 105/kg CD34+ cells; another acceptable HSC
                  back up source could be a haploidentical donor with medical clearance prior to
                  starting conditioning regimen.

               2. Must come from a cord bank that is FACT accredited, FDA approved or eligible for
                  NMDP IND

          4. Karnofsky score ≥ 70%

          5. Bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's
             disease or hemolysis; AST and ALT ≤ 2.5 x ULN; alkaline phosphatase ≤ 5 x ULN.

          6. Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2.

          7. Hematopoietic cell transplantation specific comorbidity index (HCT-CI) ≤5 for patients
             < 60 years old; HCT-CI ≤3 for patients < 60 years old and acute leukemia not in
             CR/CRi; HCT-CI ≤3 for patients 60-65 years old; HCT-CI ≤1 if 66-70 years old.

          8. Left ventricular ejection fraction ≥ 40%

          9. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing
             capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted

         10. Signed written informed consent

         11. Female patients of childbearing potential must have a negative serum pregnancy test
             within 7 days of enrolment and must be willing to use an effective contraceptive
             method while enrolled in the study.

        Exclusion Criteria:

          1. Patient never treated with cytotoxic chemotherapy and planned conditioning regimen
             does not include 12 Gy TBI (exceptions allowed if approved by PI).

          2. Allogeneic myeloablative transplant within 6 months.

          3. Autologous hematopoietic stem cell transplant within 6 months.

          4. Planned use of ATG in conditioning regimen (exceptions allowed if approved by PI in
             which case ATG must be adjusted for weight/lymphocyte count and given more than 1 week
             prior to transplant; any patient who receives ATG will have immune recovery studies
             but will not be counted with rest of patients and will be analyzed separately).

          5. Planned use of an HLA matched CB (8/8 allele matched)

          6. Uncontrolled infection.

          7. Presence of a malignancy other than the one for which the CB transplant is being
             performed, with an expected survival estimated to be less than 75% at 5 years.

          8. Seropositivity for HIV.

          9. Hepatitis B or C infection with measurable viral load. Patients with chronic hepatitis
             B or C infection regardless of viral load require clear documentation of absence of
             cirrhosis by either fibroscan or biopsy. If fibroscan is the method used, the test
             must be unequivocally negative.

         10. Liver cirrhosis.

         11. Active central nervous system involvement

         12. Chloroma > 2 cm

         13. ≥50% blasts in marrow in an evaluable marrow sample (>25% of normal cellularity for
             age) collected less than one month prior to start of conditioning regimen.

         14. Peripheral blasts >1000/mm3

         15. Pregnancy, breastfeeding or unwillingness to use appropriate contraception.

         16. Participation in a trial with an investigational agent within 30 days prior to entry
             in the study.

         17. Patient unable to give informed consent or unable to comply with the treatment
             protocol including appropriate supportive care, follow-up, and tests.

         18. Any abnormal condition or laboratory result that is considered by the PI capable of
             altering patient's condition or study outcome.
      
Maximum Eligible Age:70 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Transplant Related Mortality (TRM)
Time Frame:1 year
Safety Issue:
Description:TRM is defined as any death of any cause other than malignant relapse, occurring after the commencement of conditioning regimen that could be related to the transplantation procedure.

Secondary Outcome Measures

Measure:Neutrophil Engraftment
Time Frame:42 days
Safety Issue:
Description:Time to neutrophil engraftment is defined as the first day of attainment of an absolute neutrophil count (ANC) ≥0.5 x 109/L for 3 consecutive days. Time to ANC ≥ 0.1 x 109/L will also be documented as it seems to predict TRM.
Measure:Graft failure
Time Frame:42 days
Safety Issue:
Description:Absence of neutrophil engraftment by day 42 or secondary graft failure without any obvious cause.
Measure:Platelet Engraftment
Time Frame:60 days
Safety Issue:
Description:Platelet engraftment is defined as the first day of a sustained platelet count ≥ 20 x 109/L with no platelet transfusion in the preceding 7 days as per CIBMTR standards (www.cibmtr.org).
Measure:Incidence of Acute Graft Versus Host Disease (aGVHD)
Time Frame:1 year
Safety Issue:
Description:The time to onset and maximal grade will be recorded. Acute GVHD will be defined as classic acute (time of onset of symptoms ≤ 100 days) or persistent, recurrent, or late onset acute GVHD (time of onset of symptoms > 100 days) as defined by the NIH. Results will be compared to patients at the same institution transplanted with different stem cell sources.
Measure:Incidence of Chronic Graft Versus Host Disease (cGVHD)
Time Frame:2 years
Safety Issue:
Description:Defined as per NIH global severity scores for mild, moderate, and severe chronic GVHD.
Measure:Adverse events grade 3 or higher
Time Frame:3 years
Safety Issue:
Description:All adverse events occurring during the clinical trial, including the protocol-defined post-treatment follow-up period, qualifying as a grade ≥ 3 toxicity per the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Measure:Incidence of severe infectious complications.
Time Frame:3 years
Safety Issue:
Description:Any of the following infections requiring systemic therapy will be captured: invasive candidiasis, aspergillus, other invasive fungi, CMV, adenovirus, EBV, HHV-6, HSV, VZV, PCP, toxoplasmosis and mycobacterium.
Measure:Hospitalization events
Time Frame:1 year
Safety Issue:
Description:Total number of days admitted to the hospital in the first 100 days following transplant. Last day of fever (≥38.0°C) prior to engraftment, and number of days of parenteral feeding during transplant admission.
Measure:Incidence of preengraftment/engraftment syndrome (ES) requiring therapy.
Time Frame:30 days
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Ciusss de L'Est de l'Île de Montréal

Trial Keywords

  • UM171
  • Stem Cell Expansion

Last Updated